Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADINA: Neoadjuvant ipilimumab + nivolumab vs standard adjuvant nivolumab in stage III melanoma
2021-001492-16Phase 3Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab, ipilimumab, dabrafenib + trametinib and trametinib in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival. Started Jun 2021; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-001492-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001492-16.